These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19827100)

  • 1. On the influence of protein binding on pharmacological activity of drugs.
    Berezhkovskiy LM
    J Pharm Sci; 2010 Apr; 99(4):2153-65. PubMed ID: 19827100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dispersion model of hepatic elimination: 2. Steady-state considerations--influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity.
    Roberts MS; Rowland M
    J Pharmacokinet Biopharm; 1986 Jun; 14(3):261-88. PubMed ID: 3783447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-pass elimination. Basic concepts and clinical consequences.
    Pond SM; Tozer TN
    Clin Pharmacokinet; 1984; 9(1):1-25. PubMed ID: 6362950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic elimination of drugs with concentration-dependent serum protein binding.
    Huang JD; Oie S
    J Pharmacokinet Biopharm; 1984 Feb; 12(1):67-81. PubMed ID: 6747819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of hepatic clearance with the account of drug-protein binding kinetics.
    Berezhkovskiy LM
    J Pharm Sci; 2012 Oct; 101(10):3936-45. PubMed ID: 22767378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of plasma protein binding kinetics on hepatic clearance assessed from a "tube" model and a "well-stirred" model.
    Jansen JA
    J Pharmacokinet Biopharm; 1981 Feb; 9(1):15-26. PubMed ID: 7229915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects.
    Berezhkovskiy LM
    J Pharm Sci; 2011 Jun; 100(6):2482-97. PubMed ID: 21254063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the possibility of self-induction of drug protein binding.
    Berezhkovskiy LM
    J Pharm Sci; 2010 Oct; 99(10):4400-5. PubMed ID: 20737641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The area under the curve of metabolites for drugs and metabolites cleared by the liver and extrahepatic organs. Its dependence on the administration route of precursor drug.
    Klippert PJ; Noordhoek J
    Drug Metab Dispos; 1985; 13(1):97-101. PubMed ID: 2858385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A convenient method for estimating the quantity of drug eliminated by the routes other than hepatic metabolism and renal excretion and the fraction of drug that reaches the "first pass" after oral administration.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):828-33. PubMed ID: 16489605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The influence of drug kinetics in blood on the calculation of oral bioavailability in linear pharmacokinetics: the traditional equation may considerably overestimate the true value.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):834-48. PubMed ID: 16493592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Models of hepatic drug clearance: discrimination between the 'well stirred' and 'parallel-tube' models.
    Ahmad AB; Bennett PN; Rowland M
    J Pharm Pharmacol; 1983 Apr; 35(4):219-24. PubMed ID: 6133930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discussions on the hepatic well-stirred model: Re-derivation from the dispersion model and re-analysis of the lidocaine data.
    Dong J; Park MS
    Eur J Pharm Sci; 2018 Nov; 124():46-60. PubMed ID: 30102979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic binding and Michaelis-Menten metabolism of drugs.
    Rubin GM; Tozer TN
    J Pharm Sci; 1986 Jul; 75(7):660-3. PubMed ID: 3761165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new model-independent physiological approach to study hepatic drug clearance and its applications.
    Chiou WL
    Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):577-90. PubMed ID: 6389376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance.
    Deshmukh SV; Harsch A
    J Pharmacol Toxicol Methods; 2011; 63(1):35-9. PubMed ID: 20433934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A two-dimensional mathematical model of non-linear dual-sorption of percutaneous drug absorption.
    George K
    Biomed Eng Online; 2005 Jul; 4():40. PubMed ID: 15992411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein binding and drug clearance.
    Rowland M
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():10-7. PubMed ID: 6705422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics (second of two parts).
    Greenblatt DJ; Koch-Weser J
    N Engl J Med; 1975 Nov; 293(19):964-70. PubMed ID: 1101062
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of unbound volumes of drug distribution in pharmacokinetic calculations.
    Stepensky D
    Eur J Pharm Sci; 2011 Jan; 42(1-2):91-8. PubMed ID: 21050885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.